Literature DB >> 30489609

Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.

Xin-Zu Chen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30489609     DOI： 10.1001/jamaoncol.2018.5526

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  16 in total

1.  Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.

Authors:  Zongyang Yu; Xiuyu Cai; Zhengwu Xu; Zhiyong He; Jinhuo Lai; Wenwu Wang; Jing Zhang; Wencui Kong; Xiaoyan Huang; Ying Chen; Yanhong Shi; Xi Shi; Zhongquan Zhao; Min Ni; Xiangwu Lin; Siyu Chen; Xiaolong Wu; Wujin Chen; Zhengbo Song; Cheng Huang
Journal:  Oncologist       Date:  2020-07-25

2.  [Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].

Authors:  Ziyi Xu; Junling Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

3.  The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.

Authors:  Suying Lu; Ye Hong; Huimou Chen; Liuhong Wu; Feifei Sun; Juan Wang; Jia Zhu; Yi Que; Lian Zhang; Zijun Zhen; Xiaofei Sun; Junting Huang; Yizhuo Zhang
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

4.  miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Authors:  Leisheng Wang; He En; Lei Yang; Yanbing Zhang; Baisheng Sun; Jianjiang Gao
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

5.  Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.

Authors:  Yuejiao Zhong; Qiang Wei; You Lu; Xiuliang Tang; Zhongqiu Wang; Lingxiang Chen
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

6.  Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer.

Authors:  Liguo Yang; Xiaoshu Zhou; Jinrui Sun; Qianghui Lei; Qi Wang; Di Pan; Mingxing Ding; Yi Ding
Journal:  Cell Death Dis       Date:  2020-09-17       Impact factor: 8.469

7.  Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report.

Authors:  Peiwei Chai; Chuandi Zhou; Renbing Jia; Yefei Wang
Journal:  Diagn Pathol       Date:  2020-01-04       Impact factor: 2.644

8.  Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer.

Authors:  Qin Gao; Shan Tang; Han Chen; Hui Chen; XiaoJie Li; YiQing Jiang; ShaoZhi Fu; Sheng Lin
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 9.  Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature.

Authors:  Lei Liu; Xiang Wang; Wen-Bin Wu; Miao Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

10.  Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.

Authors:  Jianhua Shi; Guimin Chen; Haitao Wang; Xiuxiu Wang; Baohui Han; Kai Li; Qiming Wang; Li Zhang; Zhehai Wang; Ying Cheng; Jianxing He; Yuankai Shi; Weiqiang Chen; Yi Luo; Lin Wu; Xiuwen Wang; Kejun Nan; Faguang Jin; Jian Dong; Baolan Li; Zhian Liu
Journal:  Thorac Cancer       Date:  2021-07-17       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.